Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup.
OBJECTIVE
To evaluate prognostic factors for relapse-free survival (RFS) and overall survival (OS) and to assess the impact of different postremission therapies in adult patients with core binding factor (CBF) acute myeloid leukemias (AML).


METHODS
Individual patient data-based meta-analysis was performed on 392 adults (median age, 42 years; range, 16 to 60 years) with CBF AML (t(8;21), n = 191; inv(16), n = 201) treated between 1993 and 2002 in prospective German AML treatment trials.


RESULTS
RFS was 60% and 58% and OS was 65% and 74% in the t(8;21) and inv(16) groups after 3 years, respectively. For postremission therapy, intention-to-treat analysis revealed no difference between intensive chemotherapy and autologous transplantation in the t(8;21) group and between chemotherapy, autologous, and allogeneic transplantation in the inv(16) group. In the t(8;21) group, significant prognostic variables for longer RFS and OS were lower WBC and higher platelet counts; loss of the Y chromosome in male patients was prognostic for shorter OS. In the inv(16) group, trisomy 22 was a significant prognostic variable for longer RFS. For patients who experienced relapse, second complete remission rate was significantly lower in patients with t(8;21), resulting in a significantly inferior survival duration after relapse compared with patients with inv(16).


CONCLUSIONS
We provide novel prognostic factors for CBF AML and show that patients with t(8;21) who experience relapse have an inferior survival duration.
Department of Internal Medicine III, University of Ulm, Ulm, Germany.
R F
RF
Schlenk
A
A
Benner
J
J
Krauter
T
T
Büchner
C
C
Sauerland
G
G
Ehninger
M
M
Schaich
B
B
Mohr
D
D
Niederwieser
R
R
Krahl
R
R
Pasold
K
K
Döhner
A
A
Ganser
H
H
Döhner
G
G
Heil
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D050657:Core Binding Factor alpha Subunits; D004268:DNA-Binding Proteins / Q000032:analysis*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000473:pathology* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012008:Recurrence; D012737:Sex Factors; D050656:Transcription Factor AP-2; D014157:Transcription Factors / Q000032:analysis*; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D014314:Trisomy
D050657:Core Binding Factor alpha Subunits; D004268:DNA-Binding Proteins; D050656:Transcription Factor AP-2; D014157:Transcription Factors; C406688:core binding factor alpha